Joule Financial LLC Trims Stake in Eli Lilly and Company (NYSE:LLY)

Joule Financial LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 26.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 407 shares of the company’s stock after selling 144 shares during the quarter. Joule Financial LLC’s holdings in Eli Lilly and Company were worth $361,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of LLY. Stonegate Investment Group LLC grew its stake in shares of Eli Lilly and Company by 1.5% in the third quarter. Stonegate Investment Group LLC now owns 56,999 shares of the company’s stock valued at $50,498,000 after buying an additional 862 shares in the last quarter. Claro Advisors LLC increased its stake in Eli Lilly and Company by 19.0% during the third quarter. Claro Advisors LLC now owns 4,556 shares of the company’s stock worth $4,036,000 after purchasing an additional 726 shares during the period. V Square Quantitative Management LLC lifted its position in shares of Eli Lilly and Company by 9.8% during the third quarter. V Square Quantitative Management LLC now owns 14,168 shares of the company’s stock worth $12,552,000 after purchasing an additional 1,266 shares in the last quarter. CHB Investment Group LLC purchased a new position in shares of Eli Lilly and Company in the third quarter valued at approximately $2,764,000. Finally, Madrona Financial Services LLC grew its holdings in shares of Eli Lilly and Company by 12.4% in the third quarter. Madrona Financial Services LLC now owns 282 shares of the company’s stock valued at $250,000 after purchasing an additional 31 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 0.1 %

Shares of Eli Lilly and Company stock opened at $917.86 on Friday. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The company has a market capitalization of $872.34 billion, a P/E ratio of 135.18, a PEG ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 1 year low of $547.61 and a 1 year high of $972.53. The company’s fifty day moving average is $921.21 and its two-hundred day moving average is $857.37.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have commented on LLY. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, September 16th. Morgan Stanley reissued an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Berenberg Bank increased their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. BMO Capital Markets upped their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Finally, Truist Financial lifted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $986.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.